Pfizer has paused enrollment in many new and ongoing clinical trials in response to the COVID-19 pandemic, Reuters reports. The action sees Pfizer join Bristol Myers Squibb and Eli Lilly on the list of Big Pharma companies to...
Read More
In our first Pharmagin Data Insights, we looked at meeting attendance over recent years, by therapeutic area, and based on invitation lead time. You can read it here. Now in the second of our series , we’ll review Speaker...
In a recent Pharmagin blog post, we discussed the compliance challenges around speaker management – do your systems allow you to be sure speaker training, contracts, honoraria caps are handled correctly? In our continuing study of compliance-related issues, now...
In a recent Pharmagin blog post, we talked about the technical challenges that agencies will face if they chose to build or maintain their own in-house technology to manage client speaker programs, rather than letting tech experts handle it....
Following on from our recent blog Is Your Agency Digitally Mature for 2020, we’re moving into a new area of discussion. In the first of a new ongoing series of Pharmagin Data Insights, we’ll review HCP attendance at speaker...
The healthcare industry continues to be further and further enmeshed with the latest technology on all fronts. Many commentators have been highlighting this in different ways, as we head into 2020. So ask yourself – is your medcomm agency...
English